| Name | Title | Contact Details |
|---|---|---|
Pete Meyers |
Chief Financial Officer | Profile |
Basic Research, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Interspond is a Trial Management Organization (TMO) that works with a network of multi therapeutic sites across the country to facilitate clinical and pharmaceutical research and trials.
Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.
Chromocell, Corporation is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We believe that our Hypermatrix technology is a novel and robust controlled-release drug delivery platform. This unique technology allows us to provide life-cycle management or new chemical entity delivery system solutions for virtually any small molecule. The flexibility of this technology allows us to quickly develop complex drug delivery solutions.